Puddu Paolo, Puddu Giovanni Maria, Cravero Eleonora, Muscari Antonio
Department of Internal Medicine, Cardioangiology, Hepatology, University of Bologna, Italy.
Acta Cardiol. 2004 Oct;59(5):555-64. doi: 10.2143/AC.59.5.2005232.
Since endothelial dysfunction may significantly contribute to the pathophysiology of hypertension and its complications, its modification seems to be a very attractive means to favourably affect the development of atherosclerosis and cardiovascular events in hypertensive patients. However, not all antihypertensive drugs consistently improve endothelial dysfunction. While first-generation beta-blockers showed contrasting or null effects on endothelial function, newer beta-blockers of the third generation, such as carvedilol and nebivolol, seem to be provided with specific endothelium-mediated vasodilating effects. Calcium channel blockers are generally able to increase endothelium-dependent vasodilation in several vascular beds, in patients with essential hypertension, probably through multiple mechanisms. Most studies have shown thatACE inhibitors favourably affect endothelial function mainly in the subcutaneous, epicardial and renal circulation, not only by inhibiting the effects of angiotensin II on the endothelium, but also by enhancing bradykinin-induced vasodilation, probably a hyperpolarization-related effect. On the other hand, discordant evidence is available about the effects of angiotensin II receptor type I blockers on endothelial function in patients with essential hypertension, atherosclerosis or diabetes.There are data suggesting that an increased activity of the endothelin- I system may play a role in the blunted endothelium-dependent vasorelaxation of hypertensive patients, an effect that could be contrasted by the use of endothelin-I receptor antagonists. However, to date no substantial clinical efficacy of endothelin-I receptor blockers has been shown in patients with essential hypertension. Finally, other possibly useful compounds in restoring impaired endothelial function in hypertension are some antioxidant agents such as vitamin C, folic acid, the cofactor tetrahydrobiopterin (BH4), L-arginine and the drugs of the statin class.
由于内皮功能障碍可能在很大程度上导致高血压及其并发症的病理生理过程,改善内皮功能似乎是一种非常有吸引力的方法,可对高血压患者动脉粥样硬化的发展和心血管事件产生有利影响。然而,并非所有抗高血压药物都能持续改善内皮功能障碍。第一代β受体阻滞剂对内皮功能的影响呈现出相反或无效的结果,而第三代新型β受体阻滞剂,如卡维地洛和奈必洛尔,似乎具有特定的内皮介导的血管舒张作用。钙通道阻滞剂通常能够增加原发性高血压患者多个血管床的内皮依赖性血管舒张,可能是通过多种机制实现的。大多数研究表明,血管紧张素转换酶(ACE)抑制剂主要通过抑制血管紧张素II对内皮的作用,以及增强缓激肽诱导的血管舒张(可能是一种与超极化相关的效应),从而对皮下、心外膜和肾脏循环中的内皮功能产生有利影响。另一方面,关于I型血管紧张素II受体阻滞剂对原发性高血压、动脉粥样硬化或糖尿病患者内皮功能的影响,存在不一致的证据。有数据表明,内皮素-I系统活性增加可能在高血压患者内皮依赖性血管舒张减弱中起作用,使用内皮素-I受体拮抗剂可能会对抗这种效应。然而,迄今为止,内皮素-I受体阻滞剂在原发性高血压患者中尚未显示出实质性的临床疗效。最后,其他可能有助于恢复高血压患者受损内皮功能的化合物包括一些抗氧化剂,如维生素C、叶酸、辅助因子四氢生物蝶呤(BH4)、L-精氨酸以及他汀类药物。